Q32 Bio

Q32 Bio Financial Leverage

The Financial Leverage (Equity Multiplier) of Q32 Bio (QTTB) as of Oct 16, 2026 is 16.20. In the previous year, Financial Leverage (Equity Multiplier) was 1.16 — a change of 1,298.05% (higher).

Financial Leverage

16.20

YoY

1,298.05%

Last updated:

Financial Leverage (Equity Multiplier) of Q32 Bio is 2024 16.20 . Financial Leverage (Equity Multiplier) of Q32 Bio was 2023 1.16 . It decreases by 1,298.05% higher compared to the previous year.

The Q32 Bio Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2017
1.40 USD
Jan 1, 2018
1.32 USD
Jan 1, 2019
1.20 USD
Jan 1, 2020
1.35 USD
Jan 1, 2021
1.25 USD
Jan 1, 2022
1.28 USD
Jan 1, 2023
1.16 USD
Jan 1, 2024
16.20 USD
The Q32 Bio Financial Leverage history
YEARFinancial LeverageYoY
16.20+1,298.05%
1.16-9.75%
1.28+2.90%
1.25-7.28%
1.35+11.97%
1.20-8.92%
1.32-5.69%
1.40-26.12%
1.89—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Q32 Bio Stock analysis

What does Q32 Bio do? Q32 Bio Inc, trading under the ticker QTTB with ISIN US7469641051, is a biotechnology company based in Bedford, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Q32 Bio Inc has 24 employees and completed its initial public offering (IPO) on March 28, 2018. The company's website is https://www.homologymedicines.com/. While the source description provided references Homology Medicines, Inc. and includes details such as a 205-employee count, an IPO date of March 28, 2018, and a lead product candidate named HMI-102 for phenylketonuria (PKU), these details are inconsistent with the provided company profile. The factual information for Q32 Bio Inc includes its location, sector, employee count, IPO date, and website. The company is engaged in developing treatments for rare diseases at the genetic level, focusing on monogenic diseases affecting various tissues including the liver, central nervous system, bone marrow, lung, and eye. The company utilizes a platform of adeno-associated virus vectors for gene editing and therapy approaches. However, specific details about product names, additional employee figures, or other operational specifics beyond the provided data are not included in the factual profile. Q32 Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Q32 Bio stock

Financial Leverage (Equity Multiplier) of Q32 Bio is 16.20 in 2024.

Financial Leverage (Equity Multiplier) of Q32 Bio changed from 1.16 to 16.20, representing a 1,298.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Q32 Bio since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Q32 Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Q32 Bio

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Q32 Bio